TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24342820

Group type: EXPERIMENTAL
Intervention: Adaptive design in phase II trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short-term biomarker
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adaptive design
Number of subjects: 0
Study: 21936751

Group type: EXPERIMENTAL
Intervention: 12 weeks buprenorphine/naloxone (BUP; N = 74)
Number of subjects: 152

Group type: COMPARATOR
Intervention: 2-week detoxification with buprenorphine/naloxone (DETOX; N = 78)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Compensation of $5 for weekly urine drug screens and self-reported drug use information, $75 for extensive assessments at weeks 4, 8, and 12
Number of subjects: 152
Study: 19246421

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BoNT/A)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 17580725

Group type: EXPERIMENTAL
Intervention: Aided performance with hearing aids
Number of subjects: 108

Group type: COMPARATOR
Intervention: Unaided performance
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Hearing aid benefit
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Speech-recognition performance on NU-6 and CST tests
Number of subjects: 108
Study: 15866314

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 11919117

Group type: EXPERIMENTAL
Intervention: DPL (dermal Powderject lidocaine) at 40 bar with small particles
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: DPL (dermal Powderject lidocaine) at 40 bar with large particles
Number of subjects: 132

Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 132
Study: 10354658

Group type: EXPERIMENTAL
Intervention: Selegiline (10 mg per day)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study: 8923916

Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasonography for evaluating endometrial grades and hormone levels (progesterone and estradiol).
Number of subjects: 0
Study: 2025473

Group type: EXPERIMENTAL
Intervention: hyperbaric 0.5% bupivacaine 2.5 ml at L2-3 (n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: hyperbaric 0.5% bupivacaine 2.5 ml at L4-5 (n = 20)
Number of subjects: 40
Study: 7044682

Group type: EXPERIMENTAL
Intervention: Low-dose heparin prophylaxis (5000 U subcutaneously twice daily)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control group (no heparin)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Untreated medical patients
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Treated medical patients
Number of subjects: 119
Study: 31593528

Group type: EXPERIMENTAL
Intervention: Real-time feedback device
Number of subjects: 24

Group type: COMPARATOR
Intervention: Without real-time feedback device
Number of subjects: 24
Study: 30115082

Group type: EXPERIMENTAL
Intervention: Promotion of creativity (C+)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Conditions promoting creativity (C+ with or without visual display)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Promotion of creativity and omission of visual display
Number of subjects: 16

Group type: COMPARATOR
Intervention: All four training conditions
Number of subjects: 16
Study: 27367743

Group type: EXPERIMENTAL
Intervention: BBFC+PGA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle+PGA
Number of subjects: 0
Study: 24429845

Group type: EXPERIMENTAL
Intervention: Secoisolariciresinol-diglycoside (SDG) at doses of 25, 50, 75, 86, and 172 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secoisolariciresinol-diglycoside (SDG)
Number of subjects: 0
Study: 22431963

Group type: EXPERIMENTAL
Intervention: Rintatolimod (Poly I: C(12)U) 400 mg twice weekly
Number of subjects: 234

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study: 20549835

Group type: EXPERIMENTAL
Intervention: Sublingual administration of asenapine (5 mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Buccal administration of asenapine (5 mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Supralingual administration of asenapine (5 mg)
Number of subjects: 36
Study: 18257188

Group type: EXPERIMENTAL
Intervention: Acupoint-injection therapy with Jingming (BL 1), Yangbai (GB 14), Sibai (ST 2), Tongziliao (GB 1), bilateral Ganshu (BL 18), and compound Danggui Injection as the principal injected medicine.
Number of subjects: 76

Group type: COMPARATOR
Intervention: Routine western medicine therapy.
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Acupoint-injection therapy
Number of subjects: 76

Group type: COMPARATOR
Intervention: Routine western medicine therapy
Number of subjects: 76
Study: 16498927

Group type: EXPERIMENTAL
Intervention: Monophasic (120 ml at 2.5 ml/s)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low-high biphasic (120 ml, first 60 ml at 2 ml/s, the other 60 ml at 2.5 ml/s)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High-low biphasic (120 ml, first 60 ml at 2.5 ml/s, the other 60 ml at 2 ml/s)
Number of subjects: 60
Study: 12735667

Group type: EXPERIMENTAL
Intervention: Breathing retraining
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 10907802

Group type: EXPERIMENTAL
Intervention: Fluoxetine (48 mg/day, range 10 mg to 60 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8887059

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha) administered both topically and intramuscularly for 15 days
Number of subjects: 3
Study: 1712273

Group type: EXPERIMENTAL
Intervention: Cilazapril 1.25 to 5 mg daily
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Cilazapril (single dose of 2.5 or 5 mg)
Number of subjects: 33
Study: 6761849

Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 28
Study: 30738426

Group type: EXPERIMENTAL
Intervention: Ambroxol high-dose (1050 mg/day)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Ambroxol low-dose (525 mg/day)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Ambroxol (both doses)
Number of subjects: 75
Study: 28775306

Group type: EXPERIMENTAL
Intervention: Vaccine with four doses
Number of subjects: 1544

Group type: EXPERIMENTAL
Intervention: Vaccine with three doses
Number of subjects: 1544

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1544
Study: 25974251

Group type: EXPERIMENTAL
Intervention: CT-P13 in anti-TNF naïve Crohn's disease patients
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: CT-P13 in anti-TNF naïve ulcerative colitis patients
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: CT-P13 after switching from originator in Crohn's disease patients
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: CT-P13 after switching from originator in ulcerative colitis patients
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: CT-P13 in ulcerative colitis patients
Number of subjects: 74
Study: 23809312

Group type: EXPERIMENTAL
Intervention: Multiple Sclerosis Tailored Exercise Program (MSTEP)
Number of subjects: 240

Group type: COMPARATOR
Intervention: General guidelines for exercise
Number of subjects: 240
Study: 21076273

Group type: EXPERIMENTAL
Intervention: HIV-1 recombinant canarypox vaccine (vCP1452)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 19772786

Group type: EXPERIMENTAL
Intervention: Intramuscular neridronate (NE) 25 mg monthly
Number of subjects: 69
Study: 17722830

Group type: EXPERIMENTAL
Intervention: Acupuncture at Futu (LI 18), Renying (ST 9), Shuitu (ST 10) and cake-separated moxibustion at Yongquan (KI 1)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Oral administration of Huang's Xiang Sheng Pills
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Acupuncture plus moxibustion
Number of subjects: 90
Study: 15593057

Group type: EXPERIMENTAL
Intervention: Regional citrate anticoagulation (RCA)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 9
Study: 11423717

Group type: EXPERIMENTAL
Intervention: Adenosine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Exercise stress test
Number of subjects: 16
Study: 8072255

Group type: EXPERIMENTAL
Intervention: Theophylline (5 mg/kg body weight) administered intravenously 45 minutes before CM application.
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (saline) administered intravenously 45 minutes before CM application.
Number of subjects: 39
Study: 3134810

Group type: EXPERIMENTAL
Intervention: Aspirin (650 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31650662

Group type: COMPARATOR
Intervention: individual internet-based Mindfulness-Based Cognitive Therapy (eMBCT)
Number of subjects: 245

Group type: COMPARATOR
Intervention: group-based face-to-face Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: treatment as usual (TAU)
Number of subjects: 245
Study: 31412947

Group type: EXPERIMENTAL
Intervention: Prophylactic oropharyngeal exercises (respiratory muscle training, 3 times/day, 5 days/week, for 21 weeks)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard swallow therapy (control group)
Number of subjects: 52
Study: 28587977

Group type: EXPERIMENTAL
Intervention: Straight implants (S, n=37)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Tilted implants (T, n=33)
Number of subjects: 21
Study: 25705800

Group type: EXPERIMENTAL
Intervention: Low dose of hydrocortisone (0.2-0.3 mg/kg body weight/day) for 10 weeks
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: High dose of hydrocortisone (0.4-0.6 mg/kg body weight/day) for 10 weeks
Number of subjects: 47

Group type: COMPARATOR
Intervention: High dose of hydrocortisone
Number of subjects: 47
Study: 23826093

Group type: EXPERIMENTAL
Intervention: 7.2 mg nicotine cartridges for 12 weeks (Group A)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 6-week 7.2 mg nicotine cartridges followed by 6-week 5.4 mg nicotine cartridges (Group B)
Number of subjects: 300

Group type: COMPARATOR
Intervention: No-nicotine cartridges for 12 weeks (Group C)
Number of subjects: 300
Study: 21950148

Group type: EXPERIMENTAL
Intervention: 5 mg felodipine (Plendil)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 10 mg felodipine (Plendil)
Number of subjects: 100
Study: 19702377

Group type: EXPERIMENTAL
Intervention: Employee testimonials included on recruitment websites
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Video with audio testimonials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Picture with text testimonials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proportion of minorities shown in testimonials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Richer medium (video with audio)
Number of subjects: 0
Study: 16882618

Group type: EXPERIMENTAL
Intervention: GSM RadioFrequency (RF) exposure
Number of subjects: 15
Study: 15028546

Group type: EXPERIMENTAL
Intervention: Parent training (PT)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Parent plus teacher training (PT + TT)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Child training (CT)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Child plus teacher training (CT + TT)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Parent, child, plus teacher training (PT + CT + TT)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 159
Study: 11555501

Group type: EXPERIMENTAL
Intervention: Erythromycin therapy
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control (no active treatment)
Number of subjects: 109
Study: 9802627

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Multiple acute pneumonia episodes
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Baseline HIV RNA copy number and CD4+ percentage
Number of subjects: 93
Study: 8151000

Group type: EXPERIMENTAL
Intervention: Buprenorphine (4 or 8 mg/day, sublingual)
Number of subjects: 26
Study: 3276009

Group type: EXPERIMENTAL
Intervention: Clonidine (n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Chlordiazepoxide (n = 10)
Number of subjects: 20
Study: 29993218

Group type: EXPERIMENTAL
Intervention: Intratympanic lidocaine and dexamethasone (ITLD)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Intratympanic dexamethasone (ITD)
Number of subjects: 44
Study: 29206824

Group type: EXPERIMENTAL
Intervention: One-shot procedure
Number of subjects: 59

Group type: COMPARATOR
Intervention: Sequential dilatation
Number of subjects: 59
Study: 26136585

Group type: EXPERIMENTAL
Intervention: High-polyphenol-content olive oil (HPCOO; 2.7 mg/kg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Low-polyphenol-content olive oil (LPCOO; 366 mg/kg)
Number of subjects: 25
Study: 24140874

Group type: EXPERIMENTAL
Intervention: Motivational enhancement approach
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 124
Study: 20577097

Group type: EXPERIMENTAL
Intervention: Dynamic Contour Tonometry (DCT)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Goldmann Applanation Tonometry (GAT)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Central Corneal Thickness (CCT)
Number of subjects: 116
Study: 18303125

Group type: EXPERIMENTAL
Intervention: Atacicept (single subcutaneous or repeated every other week dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 16977263

Group type: EXPERIMENTAL
Intervention: Continuous Subcutaneous Insulin Infusion (CSII) with insulin lispro (n=20)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Intravenous Insulin Infusion (IVII) with regular insulin (n=13)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both CSII and IVII
Number of subjects: 33

Group type: COMPARATOR
Intervention: Intravenous Insulin Infusion (IVII)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Continuous Subcutaneous Insulin Infusion (CSII)
Number of subjects: 33
Study: 14676996

Group type: EXPERIMENTAL
Intervention: Transurethral radiofrequency energy (RFe) tissue micro‐remodeling
Number of subjects: 41
Study: 12362961

Group type: EXPERIMENTAL
Intervention: Virtual reality exposure (VRE)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Attention-placebo group treatment (GT)
Number of subjects: 45
Study: 9746961

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (58-65 Gy) with razoxane as radiosensitizer in 4 patients
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Surgery with clear margins (R-0 resection) in 5 patients, microscopic residuals (R-1) in 3, and gross residual disease in 1 patient
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combination of vindesine, razoxane, and radiotherapy in 1 patient
Number of subjects: 10
Study: 7971878

Group type: EXPERIMENTAL
Intervention: Exercise plus efficacy-based intervention
Number of subjects: 114

Group type: COMPARATOR
Intervention: Exercise plus attentional control
Number of subjects: 114
Study: 2532681

Group type: EXPERIMENTAL
Intervention: Rinse volumes of 2 ml, 5 ml, 10 ml, 15 ml, or 25 ml with air and water syringe pressures of 20/10, 20/40, 40/10, or 40/40 psi.
Number of subjects: 384

Group type: COMPARATOR
Intervention: 0 ml rinse volume with air and water syringe pressures of 20/10, 20/40, 40/10, or 40/40 psi.
Number of subjects: 384
Study: 132988

Group type: EXPERIMENTAL
Intervention: True acupuncture (needles placed into acupuncture points for low back pain)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham acupuncture (needles randomly placed in areas not related to low back pain)
Number of subjects: 30
Study: 31517791

Group type: EXPERIMENTAL
Intervention: Collaborative Chronic Care Model (CCM) implemented in outpatient mental health teams from 2015 to 2018 across 9 sites.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evidence synthesis and systematic review of randomized controlled trials of CCMs for mental health conditions.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training of 17 facilitators and engagement of 28 facilities in the CCM scale-up effort in 2017.
Number of subjects: 0
Study: 28955416

Group type: EXPERIMENTAL
Intervention: Amlodipine (5mg once daily for 4 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (25mg once daily for 4 weeks)
Number of subjects: 50
Study: 25841237

Group type: EXPERIMENTAL
Intervention: Glycopyrronium (GLY) 50 µg once daily + Salmeterol/Fluticasone (SAL/FP) 50/500 µg twice daily
Number of subjects: 773

Group type: COMPARATOR
Intervention: Tiotropium (TIO) 18 µg once daily + Salmeterol/Fluticasone (SAL/FP) 50/500 µg twice daily
Number of subjects: 773

Group type: COMPARATOR
Intervention: Placebo (PLA) + Salmeterol/Fluticasone (SAL/FP) 50/500 µg twice daily
Number of subjects: 773
Study: 24225138

Group type: EXPERIMENTAL
Intervention: Caseload midwifery
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 10
Study: 21629270

Group type: EXPERIMENTAL
Intervention: 500 ml camel milk in addition to usual care (diet, exercise, and insulin)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Usual care (diet, exercise, and insulin)
Number of subjects: 24
Study: 18073318

Group type: EXPERIMENTAL
Intervention: Secondhand smoke (SHS) exposure for 1 hour
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control trial (no SHS exposure)
Number of subjects: 28
Study: 16429457

Group type: EXPERIMENTAL
Intervention: Alpha tocopherol (AT) supplementation (134 or 268 mg/day)
Number of subjects: 32
Study: 12943173

Group type: EXPERIMENTAL
Intervention: Hachimi‐jio‐gan (HJG)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 10845009

Group type: EXPERIMENTAL
Intervention: 8 CGE (Cobalt Gray Equivalent)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 14 CGE (Cobalt Gray Equivalent)
Number of subjects: 46
Study: 9357241

Group type: EXPERIMENTAL
Intervention: 50 mg aspirin daily from day of positive ROT till 37 weeks of pregnancy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no aspirin)
Number of subjects: 50
Study: 8187656

Group type: EXPERIMENTAL
Intervention: Amodiaquine
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Pyrimethamine/sulphadoxine (P/SD)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Pyrimethamine/sulfalene (P/SL)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 73
Study: 31211612

Group type: EXPERIMENTAL
Intervention: Citrus aurantium aroma (neroli oil) inhalation, 30% essential oil in paraffin, administered three times a day
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo (paraffin)
Number of subjects: 140
Study: 29674483

Group type: EXPERIMENTAL
Intervention: Open-cell stents
Number of subjects: 1557

Group type: COMPARATOR
Intervention: Closed-cell stents
Number of subjects: 1557

Group type: EXPERIMENTAL
Intervention: Protection devices (predominantly distal filters)
Number of subjects: 1557

Group type: COMPARATOR
Intervention: No protection devices
Number of subjects: 1557
Study: 27018883

Group type: EXPERIMENTAL
Intervention: Transcorneal route
Number of subjects: 12

Group type: COMPARATOR
Intervention: Pars plana route
Number of subjects: 12
Study: 25365612

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg melatonin
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.75 mg/kg midazolam
Number of subjects: 60
Study: 22763212

Group type: EXPERIMENTAL
Intervention: 10 mL 2% lignocaine (lidocaine)
Number of subjects: 206

Group type: COMPARATOR
Intervention: 10 mL 0.5% bupivacaine
Number of subjects: 206
Study: 19744284

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 176
Study: 18929400

Group type: EXPERIMENTAL
Intervention: Robotic radical hysterectomy (RRH)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Open radical hysterectomy (ORH)
Number of subjects: 48
Study: 16444853

Group type: EXPERIMENTAL
Intervention: Enoxaparin monotherapy (1 mg/kg twice daily for 10‐18 days, then 1.5 mg/kg once daily until day 90)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Enoxaparin monotherapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Warfarin group (enoxaparin 1.0 mg/kg twice daily as a bridge to warfarin)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Warfarin group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 11830607

Group type: EXPERIMENTAL
Intervention: Cisplatin plus etoposide or paclitaxel (exact dosage and duration not specified)
Number of subjects: 574
Study: 10362172

Group type: EXPERIMENTAL
Intervention: Estrone sulfate 1.25 mg + Medroxyprogesterone acetate 2.5 mg
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: Estrone sulfate 1.25 mg + Medroxyprogesterone acetate 5 mg
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: Estrone sulfate 1.25 mg + Medroxyprogesterone acetate 10 mg
Number of subjects: 568
Study: 7543393

Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radioisotopes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined treatments (bisphosphonates, radioisotopes, local treatments)
Number of subjects: 0
Study: 1952146

Group type: EXPERIMENTAL
Intervention: Train-of-four (TOF) stimulation at 60 mA
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Double-burst stimulation (DBS3,3) at 20, 30, 50, and 60 mA
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Double-burst stimulation (DBS3,2) at 20, 30, 50, and 60 mA
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Visual assessment of fade at low currents
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Quantitative assessment of TOF and DBS
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Observer training level
Number of subjects: 51
Study: 6753109

Group type: EXPERIMENTAL
Intervention: Silymarin
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 31778115

Group type: EXPERIMENTAL
Intervention: myCompass eMH program
Number of subjects: 43631
Study: 27371291

Group type: EXPERIMENTAL
Intervention: Hamstrings tendon (HAM) graft
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bone-patellar tendon-bone (BPTB) graft
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 26074239

Group type: EXPERIMENTAL
Intervention: E. faecalis isolates from Chinese traditional food products
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: E. faecalis isolates from acidic gruel
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: E. faecalis isolates from dairy source
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: All E. faecalis isolates
Number of subjects: 43